GW Pharmaceuticals, along with its U.S. subsidiary Greenwich Biosciences, announced that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex in patients with Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy. Epidiolex is a pharmaceutical formulation of highly purified cannabidiol, a cannabinoid lacking the high associated with marijuana. In this study, both evaluated doses of Epidiolex significantly reduced the monthly frequency of drop seizures compared to placebo in highly treatment-resistant patients when added to existing treatment. “This publication in The New England Journal of Medicine marks the third time within a year that positive data for Epidiolex have been published by a top-tier, peer-reviewed journal, offering further evidence of the potential of Epidiolex as a new treatment option within the field of treatment-resistant, childhood-onset epilepsy,” said Justin Gover, GW’s Chief Executive Officer. “We are now in the latter stages of the FDA’s review of the Epidiolex New Drug Application and look forward to a decision from FDA in late June. If approved, we expect to make this important new medicine available to patients with LGS and Dravet syndrome in the second half of the year.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.